Lyell Wealth Management LP Has $15.32 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Key Points

• Lyell Wealth Management LP increased its stake in Thermo Fisher Scientific by 3.4%, acquiring an additional 1,013 shares to bring its total holdings to 30,781 shares valued at approximately $15.3 million.
• Several hedge funds have also recently increased their positions in Thermo Fisher, with Brighton Jones LLC boosting its holdings by 28.9%.
• Thermo Fisher Scientific announced a quarterly dividend of $0.43 per share, with an ex-dividend date set for September 15th, representing an annualized dividend of $1.72 and a yield of 0.36%.

Lyell Wealth Management LP increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,781 shares of the medical research company's stock after purchasing an additional 1,013 shares during the period. Thermo Fisher Scientific makes up 1.4% of Lyell Wealth Management LP's portfolio, making the stock its 17th biggest position. Lyell Wealth Management LP's holdings in Thermo Fisher Scientific were worth $15,317,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Bernard Wealth Management Corp. bought a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at about $25,000. Ameriflex Group Inc. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $30,000. IMA Advisory Services Inc. acquired a new stake in Thermo Fisher Scientific in the 1st quarter valued at approximately $35,000. Navigoe LLC acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in Thermo Fisher Scientific in the 1st quarter valued at approximately $37,000. Institutional investors own 89.23% of the company's stock.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO traded down $4.94 during trading on Friday, reaching $462.74. 2,756,840 shares of the company traded hands, compared to its average volume of 3,223,400. The company's 50 day moving average is $420.88 and its two-hundred day moving average is $467.66. The firm has a market capitalization of $174.68 billion, a PE ratio of 26.76, a PEG ratio of 2.50 and a beta of 0.74. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The company had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter in the previous year, the firm earned $5.37 EPS. Thermo Fisher Scientific's revenue was up 2.9% on a year-over-year basis. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is 9.95%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on TMO. Stifel Nicolaus dropped their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research report on Thursday, April 24th. Evercore ISI lowered their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Raymond James Financial reaffirmed an "outperform" rating and set a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Hsbc Global Res lowered Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Finally, Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target on the stock in a research report on Friday, July 11th. Six analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $593.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.